Despite a response rate between 15% and 20%, monotherapy with PD-1 inhibitors does not result in a significant improvement in OS over standard of care, suggesting that the only inhibition of PD-L1/PD-1 axis may not be enough to determine adequate levels of antitumor immunity in the HCC setting [29,30]. Here, CD274 is linked to hepatocellular carcinoma.